Bedaquiline
Cross-source consensus on Bedaquiline from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Risks & contraindications
Comparisons
Highlighted claims
- Bedaquiline's adverse event profile is mainly characterized by cardiovascular and hepatic involvement. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
- QT prolongation remained a uniquely strong bedaquiline signal compared with delamanid and pretomanid. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
- An early phase II trial led the FDA to place a black box warning on bedaquiline because of higher mortality in the bedaquiline arm, although later cohort data found lower all-cause mortality than controls. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
- Bedaquiline and delamanid shared several signals, including peripheral neuropathy, hypokalaemia, respiratory failure, seizures, and gastrointestinal or constitutional symptoms. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database
- For bedaquiline, cytotoxic metabolite generation through the CYP2E1/NF-kB pathway has been implicated in hepatotoxicity. — Real-world safety profile of novel anti-multidrug-resistant tuberculosis drugs: a disproportionality analysis based on the FAERS database